Brief: Cyclacel Pharmaceuticals Reviews 2022 Achievements

Bio Green Med Solution

05/01/2023 15:52

Jan 5 (Reuters) - Cyclacel Pharmaceuticals Inc  CYCC.O :
    * CYCLACEL PHARMACEUTICALS REVIEWS 2022 ACHIEVEMENTS AND
ANNOUNCES
KEY BUSINESS OBJECTIVES FOR 2023
    * CYCLACEL PHARMACEUTICALS INC - EXPECTING KEY DATA READOUTS
FOR
ORAL FADRACICLIB IN 2023
    * CYCLACEL PHARMACEUTICALS INC - EXISTING CASH UNTIL END OF
2023
SUPPORT MULTIPLE DATA READOUTS
    * CYCLACEL PHARMACEUTICALS INC - 2/3 PARTIAL RESPONSES IN
LYMPHOMA
AND 11/15 STABLE DISEASE IN ADVANCED SOLID TUMORS
    * CYCLACEL PHARMACEUTICALS INC - EXPECTING PRELIMINARY
SAFETY AND
EFFICACY UPDATE FOR ORAL PLOGOSERTIB IN ADVANCED SOLID TUMORS IN
1H 2023
    * CYCLACEL PHARMACEUTICALS INC - DETERMINATION OF
RECOMMENDED
PHASE 2 DOSE AND START OF PHASE 2 IN 1Q 2023 FOR ORAL
FADRACICLIB

Source text for Eikon:  ID:nGNXqs9vc 
Further company coverage:  CYCC.O 
 ((Reuters.Briefs@thomsonreuters.com;))